BioNTech (NASDAQ:BNTX) CEO Sells 34,000 Shares of Stock

Posted by Geri Gentry on Sep 16th, 2026

BioNTech SE Sponsored ADR (NASDAQ:BNTX – Get Free Report) CEO Ugur Sahin sold 34,000 shares of the business’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $96.49, for a total transaction of $3,280,660.00. Following the sale, the chief executive officer directly owned 568,209 shares of the company’s stock, valued at $54,826,486.41. This represents a 5.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total transaction of $1,441,350.00.
On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The shares were sold at an average price of $99.45, for a total transaction of $4,077,450.00.
On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $96.93, for a total value of $4,361,850.00.
On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The stock was sold at an average price of $96.31, for a total value of $1,974,355.00.
On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The shares were sold at an average price of $97.78, for a total value of $3,520,080.00.
On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total value of $3,670,400.00.
On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total value of $3,260,880.00.
On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total value of $4,628,250.00.

BioNTech Price Performance

Shares of BNTX traded down $0.86 during trading hours on Wednesday, hitting $95.83. 407,411 shares of the stock were exchanged, compared to its average volume of 1,104,336. The stock’s 50-day moving average price is $97.13 and its two-hundred day moving average price is $95.10. BioNTech SE Sponsored ADR has a 12-month low of $79.52 and a 12-month high of $124.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. The company has a market cap of $24.23 billion, a price-to-earnings ratio of -12.24 and a beta of 1.29.

BioNTech (NASDAQ:BNTX – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The firm had revenue of $122.31 million during the quarter, compared to analysts’ expectations of $180.18 million. During the same quarter in the previous year, the business posted ($1.60) EPS. The company’s revenue for the quarter was down 59.5% on a year-over-year basis. Research analysts expect that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on BNTX. Sanford C. Bernstein restated a “market perform” rating on shares of BioNTech in a report on Friday, June 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a research report on Monday, July 6th. Jefferies Financial Group reiterated a “buy” rating on shares of BioNTech in a research report on Monday, June 1st. Morgan Stanley reduced their price target on shares of BioNTech from $126.00 to $119.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 8th. Finally, Canaccord Genuity Group decreased their price objective on shares of BioNTech from $142.00 to $136.00 and set a “buy” rating on the stock in a report on Monday, August 31st. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, BioNTech currently has an average rating of “Moderate Buy” and a consensus price target of $126.00.

Check Out Our Latest Stock Analysis on BioNTech

Hedge Funds Weigh In On BioNTech

Several hedge funds have recently bought and sold shares of BNTX. Larson Financial Group LLC grew its stake in shares of BioNTech by 86.4% during the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares during the period. AlphaCentric Advisors LLC boosted its holdings in BioNTech by 5.7% during the first quarter. AlphaCentric Advisors LLC now owns 5,616 shares of the company’s stock worth $499,000 after buying an additional 305 shares in the last quarter. USS Investment Management Ltd boosted its holdings in BioNTech by 1.2% during the first quarter. USS Investment Management Ltd now owns 32,577 shares of the company’s stock worth $2,854,000 after buying an additional 382 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in BioNTech during the second quarter worth about $39,000. Finally, Marks Group Wealth Management Inc grew its holdings in shares of BioNTech by 16.0% in the 1st quarter. Marks Group Wealth Management Inc now owns 3,454 shares of the company’s stock worth $307,000 after acquiring an additional 476 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

(Get Free Report)

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.